IMRT/Pemetrexed/Cisplatin in Esophageal Cancer

• Conditions: Esophageal Cancer

• Registration Number: NCT01630174
• Lead Sponsor: Shandong Cancer Hospital and Institute

Brief Summary

To evaluate the effect of concomitant late course accelerated hyperfractionation radiochemotherapy with pemetrexed and cisplatin in patients with esophagus cancer

Detailed Description

Not available

Study Timeline

• Study Start: 2009-10
• Status Verified: 2012-06
• Study First Submitted: 2012-06-27
• Study First Submitted QC: 2012-06-27
• Last Update Submitted: 2012-06-27
• Study First Posted: 2012-06-28
• Last Update Posted: 2012-06-28

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Signed informed consent; 2.Acquired pathological diagnosis; 3.Life expectancy≥6 months; 4.Age:18-75 years, male or female; 5.General state of health: ECOG 0-1 grade; 6.Without any chemotherapy or radiotherapy; 7.Subjects meet the following criteria for the clinical laboratory:HG≥100g/L, WBC≥3.5X109 /L, neutrophilic leukocyte≥1.5X109,PLT100X109 /L。CR≤1.5 x N，TB≤2.5XN，AST and ALT≤2.5xN，AKP≤2.5XN.

Exclusion Criteria

• 1.Serious infection; 2.Uncontrollable diabetes; 3.Other serious diseases, such as myocardial infarction in 6 months; 4. Participated other clinical trials in 4 weeks or at present

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Shandong Cancer hospital and institute; 🇨🇳 Jinan, Shandong, China